ClinicalTrials.gg
CompletedNCT05292586FORCE2Updated Jul 20, 2026Results posted

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

A Phase 3 interventional study of Beclomethasone Dipropionate/Formoterol Fumarate and Beclomethasone Dipropionate in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 91 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,377
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
2nd of 40
1,377 · median 67
Started
2022
with 1 other
Phase 3
20 of 40
none open now
Registered
39th of 40
by date
Lead sponsor
12 of 40
Chiesi Farmaceutici S.p.A.

Among the 40 studies testing beclomethasone in Asthma, this one is the 2nd largest by enrollment, is one of 2 that started in 2022, is one of 20 in phase 3, and was the 39th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

Compare the superiority of CHF 1535 versus CHF 718 in subjects with asthma who are on medium or high dose inhaled corticosteroids.

Read the detailed description

This was a phase III, multicenter, randomized, double-blind active controlled 2-arm parallel group to compare superiority of CHF 1535 pressurised metered dose inhaler (pMDI) compared with CHF 718 pMDI, in subjects with asthma on medium or high dose inhaled corticosteroids, with regard to change from baseline in forced expiratory volume in the first second (FEV1) Area under the Curve Calculated Between Time 0 and 12 Hours (AUC0-12h) at Week 12.

After screening, eligible subjects entered a 2-week run-in period using CHF 718 (BDP) pMDI 100µg, followed by a 12-week double-blind, treatment period. Screened subjects who were on a medium dose inhaled corticosteroid (ICS) or medium dose ICS-long-acting β2-adrenergic receptor agonists (LABA) prior to the study, received CHF 718 pMDI 100µg 2 inhalations twice daily (BID) i.e. total daily dose (TDD) 400µg) during the 2-week run in period. Screened subjects who were on a high dose ICS prior to the study received CHF 718 pMDI 100µg 4 inhalations BID (TDD 800µg) during the 2-week run in period.

Following the run-in period, eligible subjects were randomized to one of two study drug arms (using a 1:1 allocation ratio) for 12 weeks. A total of 6 clinic visits (V), (V0-V5) and a follow-up call (V6) were performed during the study.

During the study, daily symptoms, rescue medication use, and compliance with the study drug were recorded via a subject-specific electronic diary (eDiary). Concomitant medications and adverse events (AEs) were assessed and recorded throughout the study. Vital signs measurements, physical exam, 12-lead electrocardiogram (ECG), peak expiratory flow (PEF), and spirometry measurements, including serial spirometry were performed and recorded. Symptoms were assessed using disease specific questionnaires. Routine hematology, blood chemistry, and urine pregnancy testing were performed before enrolment and at the end of study.

CHF 1535 pMDI = 200/6 μg pressurised metered dose inhaler (fixed combination of extrafine beclomethasone dipropionate [BDP] plus formoterol fumarate [FF]).

CHF 718 pMDI = 100 μg pressurised metered dose inhaler (extrafine beclomethasone dipropionate [BDP]).

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Beclomethasone Dipropionate
  • Beclometasone dipropionate/Formoterol fumarate
  • Inhaled Corticosteroids
  • CHF 1535 pMDI
  • CHF 718 pMDI
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. : A signed and dated written informed consent obtained prior to any study-related procedures.
  2. Sex and age: Male or female aged ≥18 and ≤75 years.
  3. Diagnosis of asthma: A documented history of asthma for at least 1 year, with onset before age 40
  4. Stable asthma therapy: Use of medium-dose ICS with or without a LABA or high-dose ICS alone for 3 months (at a stable dose for at least 4 weeks prior to screening).
  5. Lung function: Subjects with a pre-bronchodilator ≥40% and ≤85% of predicted, after appropriate from bronchodilators, at the screening and randomization visits. In addition, the absolute value of the first pre-dose FEV1 at randomization (V2) must be at least 80% of the pre-bronchodilator value attained at screening.
  6. Reversibility post-bronchodilator: Subjects with a positive reversibility to bronchodilator at screening, defined as an increase in FEV1 > 12% and > 200mL compared to baseline within 30 minutes after 4 inhalations of albuterol hydrofluoroalkane (HFA) pMDI 90µg/actuation.

    Note for IC#5 and IC#6: In case the reversibility and/or quality threshold is not met at screening, the test can be performed once before randomization.

  7. Female subjects:

    a. Women of (WOCBP) fulfilling one of the following criteria: i. WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective method from the signing of the informed consent form and until the follow-up contact or ii. WOCBP with non-fertile male partners (contraception is not required in this case).

    b. Female subjects of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. or permanently sterile as per definitions given in Appendix 2). Tubal ligation or partial surgical interventions are not acceptable. If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges).

  8. Cooperative attitude and ability to demonstrate correct use of the pMDI inhalers and eDiary/peak flow meter.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation: where pregnancy is defined as the state of a female after conception and until termination of the gestation, confirmed by a positive pregnancy test (serum and urine pregnancy test to be performed at screening visit and urine pregnancy test to be performed prior to randomization).
  2. Poor compliance with run-in medication or eDiary completion \<50% before randomization.
  3. History of "at risk" asthma: History of near-fatal asthma or of a past hospitalization for asthma in intensive care unit which, in the judgement of the investigator, may place the subject at undue risk.
  4. Recent asthma exacerbation: Hospitalization, emergency room admission or use of systemic for an asthma exacerbation in the 4 weeks prior to screening visit or during the run-in period.
  5. Unresolved respiratory tract infection (RTI) in the 4 weeks prior to the screening visit or during run-in period. Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks or complications from this disease, which have not resolved within 14 days prior to screening.
  6. Unstable ICS dose during the 4 weeks prior to screening visit, including any change in dose, schedule, or formulation.
  7. Use of systemic corticosteroid medication in the 4 weeks prior to screening or slow-release corticosteroids in the 12 weeks before screening.
  8. Respiratory disorders other than asthma: History of a diagnosis of cystic fibrosis, bronchiectasis, (COPD), (as defined by the current Global Initiative for Chronic Obstructive Lung Disease [GOLD] Report), alpha-1 antitrypsin deficiency, or any other significant lung disease which may interfere with study evaluations.
  9. Smoking status: Current smokers or ex-smokers with total cumulative exposure equal to or more than 10 pack-years or having stopped smoking within one year prior to screening visit.
  10. E-cigarette status: Current e-cigarettes users at the time of the screening visit.
  11. Cannabis usage: Current use of inhaled or oral cannabis products (e.g. marijuana).
  12. Substance abuse: Subjects with a history of alcohol or substance/drug abuse within 12 months prior to screening.
  13. Cardiovascular diseases: Subjects who have cardiovascular condition such as, but not limited to, unstable ischemic heart disease, (NYHA) Class III/IV heart failure, acute ischemic heart disease within one year prior to study entry, known history of atrial fibrillation or history of sustained and non-sustained cardiac arrhythmias diagnosed within the last 6 months prior to screening, not controlled with a rate control strategy. Note: Subjects with Permanent Atrial Fibrillation (for at least 6 months) with a resting ventricular rate \<100/min, controlled with a rate control strategy (i.e., selective β-blocker, calcium channel blocker, pacemaker placement, digoxin, or ablation therapy) can be considered for the enrollment.
  14. criteria: An abnormal and clinically significant 12-lead electrocardiogram (ECG) which may impact the safety of the subject according to Investigator's judgement. In terms of the , subjects with QTcF >450ms for males or QTcF >470ms for females at screening or at randomization visits (criterion not applicable for subject with pacemaker or permanent atrial fibrillation).
  15. Other medical conditions: Other active severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  16. Vaccination: Subjects having received a vaccination within 2 weeks prior to screening or during the run-in period.
  17. Subjects' wellbeing: Subjects mentally or legally incapacitated, including but not limited to subjects who are institutionalized or incarcerated.
  18. : Subjects with known intolerance, hypersensitivity or to treatment with ß2-agonists, ICS, or propellant gases/.
  19. Surgery: Subjects with major surgery in the 3 months prior to the screening visit or planned surgery during the study.
  20. Additional treatment: Subjects treated with non-potassium sparing diuretics (unless administered as a fixed-dose combination with a potassium conserving drug or changed to potassium sparing before the screening), non-selective beta-blocking drugs, quinidine, quinidine-like anti-arrhythmic, or any medication with a QTc prolongation potential or a history of QTc prolongation.
  21. Subjects treated with monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants.
  22. Subjects with concomitant therapy, use of oral or injected corticosteroids, anti-immunoglobulin E (IgE), anti-IL5 or other monoclonal or polyclonal antibodies within 12 weeks prior to screening.
  23. Subjects who are receiving any therapy that could interfere with the study drugs according to investigator's opinion.
  24. Participating in other trial: Subjects who have received an investigational drug within 1 month or 5 half-lives (whichever is greater) prior to screening visit, or have been previously randomized in this trial, or are currently participating in another clinical trial.
  25. Spacer: The need to use a spacer for correct self-administration of a pMDI.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,377 participants (actual)

Study arms

  • Experimental
    CHF 1535 pMDI

    CHF 1535 pMDI 800/24µg TDD

    Drug: Beclomethasone Dipropionate/Formoterol Fumarate

  • Active comparator
    CHF 718 pMDI

    CHF 718 pMDI 800µg TDD

    Drug: Beclomethasone Dipropionate

Interventions

  • DrugBeclomethasone Dipropionate/Formoterol Fumarate

    Drug pages: Beclomethasone · Formoterol

    Available in pressurized inhalation solution BDP/FF 200/6 µg

    Also known as: BDP/FF

  • Available in pressurized inhalation solution BDP 100 µg

    Also known as: BDP

06

What researchers measure

Primary outcomes

  1. 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12

    The pre-dose FEV1 at baseline (i.e. pre-dose on Week 0 \[Visit 2\]) and the FEV1 AUC0-12h normalised by time at Week 12 (Visit 5) are presented by treatment group in the ITT population, as change from baseline. AUC0=12h Area under the curve calculated between time 0 and 12 hours

    Time frame: Baseline (pre-dose on Week 0) and Week 12.

Secondary outcomes

  1. 2_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 12

    The peak FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the peak FEV1 within the first 3 hours post-dose at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second

    Time frame: Baseline (pre-dose on Week 0) and Week 12.

  2. 3_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 0

    The pre-dose FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the FEV1 AUC0-12h normalised by time at Week 0 (V2, post-dose) are presented by treatment group in the ITT population, as change from baseline.

    Time frame: Baseline (pre-dose on Week 0) and Week 12.

  3. 4_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 0

    The peak FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the peak FEV1 within the first 3 hours post-dose at Week 0 (V2, post-dose) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second

    Time frame: Baseline (pre-dose on Week 0) and 3 h post dose on Week 0.

  4. 5_Change From Baseline in Trough FEV1 at Week 12

    The trough FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]), the trough FEV1 at Week 12 (V5) and the change from baseline in trough FEV1 at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second

    Time frame: Baseline (pre-dose on Week 0) and Week 12.

  5. 6_Change From Baseline in Pre-dose Morning FEV1 at Weeks 4, 8 and 12

    The pre-dose MORNING FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the pre-dose morning FEV1 at Week 4 (V3), Week 8 (V4) and Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second

    Time frame: Baseline (pre-dose on Week 0) and Week 4, Week 8, Week 12.

  6. 7_Proportion of Pre-dose Morning FEV1 Responders at Weeks 4, 8 and 12

    The proportion of pre-dose MORNING FEV1 responders at Week 4 (V3), Week 8 (V4) and Week 12 (V5) are presented by treatment group in the ITT population. The proportion of subjects classified as pre-dose morning FEV1 responders (i.e. those subjects who had change from baseline in pre-dose morning FEV1 ≥100 mL). FEV1=Forced Expiratory Volume in the First Second

    Time frame: Baseline (pre-dose on Week 0) and Week 4, Week 8, Week 12.

  7. 8_Proportion of Trough FEV1 Responders at Week 12

    The proportion of trough FEV1 responders at Week 12 (V5) are presented by treatment group in the ITT population. The proportion of subjects classified as trough FEV1 responders (i.e. those subjects who had change from baseline in trough FEV1 ≥100 mL). FEV1=Forced Expiratory Volume in the First Second

    Time frame: Baseline (pre-dose on Week 0) and Week 4, Week 8, Week 12.

  8. 9_Change From Baseline in Average Morning Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period

    The average MORNING PEF at baseline (i.e. average morning "Best PEF" values during the run-in period, over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population), as change from baseline. PEF=Peak Expiratory Flow

    Time frame: Baseline (Week 0) to Week 12.

  9. 10_Change From Baseline in Average Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period

    The average EVENING PEF at baseline (i.e. average evening "Best PEF" values during the run-in period, see Section 9.7.1.4), over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline. PEF=Peak Expiratory Flow

    Time frame: Baseline (Week 0) to Week 12.

  10. 11_Change From Baseline in ACQ-7 Score and ACQ-5 Score at Week 12

    The ACQ-7 and ACQ-5 scores at baseline (i.e. pre-dose on Week 0 \[V2\]) and at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline; only patients who provided required data at baseline and at specified times are included in the calculation. Asthma control was evaluated during the treatment period (Week 0 to Week 12 \[V2-V5\])/end of treatment (ET) if applicable, using ACQ-7; first 6 items refer to symptoms and rescue use in the previous 7 days. The 7th item, filled in by the clinical staff, was the FEV1 (% predicted) recorded at 15 min pre-dose, measured at each visit during the treatment period. ACQ-5 has 5 items on adequacy of asthma control. ACQ-7: Assess asthma symptoms over last 7 days (night-time awakenings due to symptoms, morning symptoms, activity limitation, shortness of breath, wheezing), average daily rescue medication use, and current FEV1 percent predicted. Score scale: 0=totally controlled; 6=severely uncontrolled.

    Time frame: Baseline (pre-dose on Week 0) and Week 12.

  11. 12_Change From Baseline in Percentage of Rescue Medication-free Days Over the 12-Week Treatment Period

    The percentage of rescue medication-free days at baseline (i.e. percentage of days during the run-in period with no rescue medication), over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline.

    Time frame: Baseline (pre-dose on Week 0) and Week 12.

  12. 13_Change From Baseline in Percentage of Asthma Symptom-free Days Over the 12-Week Treatment Period

    The percentage of asthma symptom-free days at baseline (i.e. percentage of days during the run-in period with no asthma symptom, over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline.

    Time frame: Baseline (pre-dose on Week 0) and Week 12.

07

Results

Posted Sep 4, 2025

Participant flow

Overall, 1377 participants were enrolled into the study; of these, 576 met eligibility criteria and were randomized to treatment.

Participant flow — Overall Study
MilestoneCHF 1535 pMDICHF 718 pMDI
Started287289
Completed276267
Not completed1122
Withdrew: Withdrawal by subject310
Withdrew: Randomization error37
Withdrew: Adverse event30
Withdrew: Lost to follow-up01
Withdrew: Patient refused treatment10
Withdrew: Patient could not travel to the study site10
Withdrew: Technical issues with the masterscope03
Withdrew: Patient moved to a different state01

Outcome measures

Primary1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12

The pre-dose FEV1 at baseline (i.e. pre-dose on Week 0 \[Visit 2\]) and the FEV1 AUC0-12h normalised by time at Week 12 (Visit 5) are presented by treatment group in the ITT population, as change from baseline. AUC0=12h Area under the curve calculated between time 0 and 12 hours

Time frame:
Baseline (pre-dose on Week 0) and Week 12.
Reported as:
Least squares mean · liter
1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12
literCHF 1535 pMDICHF 718 pMDI
1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 120.279 (0.248 to 0.309)0.174 (0.143 to 0.206)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = <0.001 · Adjusted mean difference: 0.104 · 95% CI 0.061 to 0.148
Secondary2_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 12

The peak FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the peak FEV1 within the first 3 hours post-dose at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second

Time frame:
Baseline (pre-dose on Week 0) and Week 12.
Reported as:
Least squares mean · liter
2_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 12
literCHF 1535 pMDICHF 718 pMDI
2_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 120.419 (0.385 to 0.453)0.295 (0.260 to 0.330)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = <0.001 · Adjusted mean difference: 0.124 · 95% CI 0.076 to 0.173
Secondary3_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 0

The pre-dose FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the FEV1 AUC0-12h normalised by time at Week 0 (V2, post-dose) are presented by treatment group in the ITT population, as change from baseline.

Time frame:
Baseline (pre-dose on Week 0) and Week 12.
Reported as:
Least squares mean · liter
3_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 0
literCHF 1535 pMDICHF 718 pMDI
3_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 00.250 (0.223 to 0.276)0.149 (0.122 to 0.175)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = <0.001 · Adjusted mean difference: 0.101 · 95% CI 0.063 to 0.139
Secondary4_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 0

The peak FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the peak FEV1 within the first 3 hours post-dose at Week 0 (V2, post-dose) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second

Time frame:
Baseline (pre-dose on Week 0) and 3 h post dose on Week 0.
Reported as:
Least squares mean · liter
4_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 0
literCHF 1535 pMDICHF 718 pMDI
4_Change From Baseline in Peak FEV1 Within the First 3 Hours Post-dose at Week 00.374 (0.345 to 0.404)0.262 (0.233 to 0.291)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = <0.001 · Adjusted mean difference: 0.113 · 95% CI 0.071 to 0.154
Secondary5_Change From Baseline in Trough FEV1 at Week 12

The trough FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]), the trough FEV1 at Week 12 (V5) and the change from baseline in trough FEV1 at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second

Time frame:
Baseline (pre-dose on Week 0) and Week 12.
Reported as:
Least squares mean · liter
5_Change From Baseline in Trough FEV1 at Week 12
literCHF 1535 pMDICHF 718 pMDI
5_Change From Baseline in Trough FEV1 at Week 120.212 (0.179 to 0.244)0.143 (0.110 to 0.176)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.003 · Adjusted mean difference: 0.069 · 95% CI 0.023 to 0.115
Secondary6_Change From Baseline in Pre-dose Morning FEV1 at Weeks 4, 8 and 12

The pre-dose MORNING FEV1 at baseline (i.e. pre-dose on Week 0 \[V2\]) and the pre-dose morning FEV1 at Week 4 (V3), Week 8 (V4) and Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline. FEV1=Forced Expiratory Volume in the First Second

Time frame:
Baseline (pre-dose on Week 0) and Week 4, Week 8, Week 12.
Reported as:
Least squares mean · liter
6_Change From Baseline in Pre-dose Morning FEV1 at Weeks 4, 8 and 12
literCHF 1535 pMDICHF 718 pMDI
Week 4 (V3)0.152 (0.121 to 0.182)0.107 (0.076 to 0.139)
Week 8 (V4)0.188 (0.154 to 0.222)0.147 (0.113 to 0.182)
Week 12 (V5)0.162 (0.132 to 0.193)0.120 (0.088 to 0.151)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.050 · Adjusted mean difference: 0.044 · 95% CI 0.000 to 0.088
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.098 · Adjusted mean difference: 0.041 · 95% CI -0.007 to 0.089
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.056 · Adjusted mean difference: 0.043 · 95% CI -0.001 to 0.086
Secondary7_Proportion of Pre-dose Morning FEV1 Responders at Weeks 4, 8 and 12

The proportion of pre-dose MORNING FEV1 responders at Week 4 (V3), Week 8 (V4) and Week 12 (V5) are presented by treatment group in the ITT population. The proportion of subjects classified as pre-dose morning FEV1 responders (i.e. those subjects who had change from baseline in pre-dose morning FEV1 ≥100 mL). FEV1=Forced Expiratory Volume in the First Second

Time frame:
Baseline (pre-dose on Week 0) and Week 4, Week 8, Week 12.
Reported as:
Count of participants · Participants
7_Proportion of Pre-dose Morning FEV1 Responders at Weeks 4, 8 and 12
ParticipantsCHF 1535 pMDICHF 718 pMDI
Week 4 (V3)154130
Week 8 (V4)162141
Week 12 (V5)162125
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · Logistic regression model · p = 0.098 · Odds ratio (or): 1.327 · 95% CI 0.949 to 1.855
  • CHF 1535 pMDI vs CHF 718 pMDI · Logistic regression model · p = 0.180 · Odds ratio (or): 1.262 · 95% CI 0.898 to 1.772
  • CHF 1535 pMDI vs CHF 718 pMDI · Logistic regression model · p = 0.009 · Odds ratio (or): 1.568 · 95% CI 1.117 to 2.203
Secondary8_Proportion of Trough FEV1 Responders at Week 12

The proportion of trough FEV1 responders at Week 12 (V5) are presented by treatment group in the ITT population. The proportion of subjects classified as trough FEV1 responders (i.e. those subjects who had change from baseline in trough FEV1 ≥100 mL). FEV1=Forced Expiratory Volume in the First Second

Time frame:
Baseline (pre-dose on Week 0) and Week 4, Week 8, Week 12.
Reported as:
Count of participants · Participants
8_Proportion of Trough FEV1 Responders at Week 12
ParticipantsCHF 1535 pMDICHF 718 pMDI
8_Proportion of Trough FEV1 Responders at Week 12181136
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · Logistic regression model · p = <0.001 · Odds ratio (or): 1.822 · 95% CI 1.284 to 2.587
Secondary9_Change From Baseline in Average Morning Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period

The average MORNING PEF at baseline (i.e. average morning "Best PEF" values during the run-in period, over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population), as change from baseline. PEF=Peak Expiratory Flow

Time frame:
Baseline (Week 0) to Week 12.
Reported as:
Least squares mean · liter/min
9_Change From Baseline in Average Morning Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period
liter/minCHF 1535 pMDICHF 718 pMDI
9_Change From Baseline in Average Morning Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period13.45 (9.58 to 17.32)4.67 (0.77 to 8.56)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.002 · Adjusted mean difference: 8.78 · 95% CI 3.30 to 14.27
Secondary10_Change From Baseline in Average Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period

The average EVENING PEF at baseline (i.e. average evening "Best PEF" values during the run-in period, see Section 9.7.1.4), over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline. PEF=Peak Expiratory Flow

Time frame:
Baseline (Week 0) to Week 12.
Reported as:
Least squares mean · liter/min
10_Change From Baseline in Average Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period
liter/minCHF 1535 pMDICHF 718 pMDI
10_Change From Baseline in Average Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period10.27 (6.46 to 14.08)1.54 (-2.31 to 5.38)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.002 · Adjusted mean difference: 8.73 · 95% CI 3.32 to 14.14
Secondary11_Change From Baseline in ACQ-7 Score and ACQ-5 Score at Week 12

The ACQ-7 and ACQ-5 scores at baseline (i.e. pre-dose on Week 0 \[V2\]) and at Week 12 (V5) are presented by treatment group in the ITT population, as change from baseline; only patients who provided required data at baseline and at specified times are included in the calculation. Asthma control was evaluated during the treatment period (Week 0 to Week 12 \[V2-V5\])/end of treatment (ET) if applicable, using ACQ-7; first 6 items refer to symptoms and rescue use in the previous 7 days. The 7th item, filled in by the clinical staff, was the FEV1 (% predicted) recorded at 15 min pre-dose, measured at each visit during the treatment period. ACQ-5 has 5 items on adequacy of asthma control. ACQ-7: Assess asthma symptoms over last 7 days (night-time awakenings due to symptoms, morning symptoms, activity limitation, shortness of breath, wheezing), average daily rescue medication use, and current FEV1 percent predicted. Score scale: 0=totally controlled; 6=severely uncontrolled.

Time frame:
Baseline (pre-dose on Week 0) and Week 12.
Reported as:
Least squares mean · score
11_Change From Baseline in ACQ-7 Score and ACQ-5 Score at Week 12
scoreCHF 1535 pMDICHF 718 pMDI
ACQ-7-0.414 (-0.484 to -0.345)-0.302 (-0.373 to -0.231)
ACQ-5-0.413 (-0.481 to -0.345)-0.433 (-0.503 to -0.364)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.026 · Adjusted mean difference: -0.112 · 95% CI -0.211 to -0.013
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.686 · Adjusted mean difference: 0.020 · 95% CI -0.077 to 0.118
Secondary12_Change From Baseline in Percentage of Rescue Medication-free Days Over the 12-Week Treatment Period

The percentage of rescue medication-free days at baseline (i.e. percentage of days during the run-in period with no rescue medication), over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline.

Time frame:
Baseline (pre-dose on Week 0) and Week 12.
Reported as:
Least squares mean · percentage of days
12_Change From Baseline in Percentage of Rescue Medication-free Days Over the 12-Week Treatment Period
percentage of daysCHF 1535 pMDICHF 718 pMDI
12_Change From Baseline in Percentage of Rescue Medication-free Days Over the 12-Week Treatment Period17.923 (15.457 to 20.388)14.103 (11.617 to 16.589)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.033 · Adjusted mean difference: 3.820 · 95% CI 0.310 to 7.330
Secondary13_Change From Baseline in Percentage of Asthma Symptom-free Days Over the 12-Week Treatment Period

The percentage of asthma symptom-free days at baseline (i.e. percentage of days during the run-in period with no asthma symptom, over each inter-visit period and over the 12-week treatment period are presented by treatment group in the ITT population, as change from baseline.

Time frame:
Baseline (pre-dose on Week 0) and Week 12.
Reported as:
Least squares mean · percentage of days
13_Change From Baseline in Percentage of Asthma Symptom-free Days Over the 12-Week Treatment Period
percentage of daysCHF 1535 pMDICHF 718 pMDI
13_Change From Baseline in Percentage of Asthma Symptom-free Days Over the 12-Week Treatment Period20.872 (17.908 to 23.836)17.092 (14.098 to 20.086)
Statistical analysis
  • CHF 1535 pMDI vs CHF 718 pMDI · ANCOVA · p = 0.078 · Adjusted mean difference: 3.780 · 95% CI -0.425 to 7.985

Adverse events

Collected over Adverse events (AE) were reported from the time of patient informed consent signature until study completion at week 12 or at study discontinuation.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CHF 1535 pMDI0/283 (0%)3/283 (1.1%)44/283 (15.5%)
CHF 718 pMDI0/280 (0%)0/280 (0%)53/280 (18.9%)
Most frequent serious events
Most frequent serious events
EventCHF 1535 pMDICHF 718 pMDI
OsteomyelitisInfections and infestations1/2830/280
Pneumonia influenzalInfections and infestations1/2830/280
AsthmaRespiratory, thoracic and mediastinal disorders1/2830/280
Spinal cord injuryInjury, poisoning and procedural complications1/2830/280
Thoracic spinal stenosisMusculoskeletal and connective tissue disorders1/2830/280
Spinal cord compressionNervous system disorders1/2830/280
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCHF 1535 pMDICHF 718 pMDI
AsthmaRespiratory, thoracic and mediastinal disorders6/28314/280
Upper respiratory tract infectionInfections and infestations6/2838/280
NasopharyngitisInfections and infestations8/2837/280
Oral candidiasisInfections and infestations3/2835/280
HeadacheNervous system disorders3/2835/280
Muscle spasmsMusculoskeletal and connective tissue disorders5/2830/280
CoughRespiratory, thoracic and mediastinal disorders5/2831/280
Back painMusculoskeletal and connective tissue disorders3/2834/280
COVID-19Infections and infestations4/2833/280
VomitingGastrointestinal disorders1/2833/280

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CHF 1535 pMDICHF 718 pMDITotal
<=18 years000
Between 18 and 65 years231237468
>=65 years524395
Age, Continuous
Age, Continuous(years)CHF 1535 pMDICHF 718 pMDITotal
Mean51.6 ± 14.150.3 ± 14.150.9 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)CHF 1535 pMDICHF 718 pMDITotal
Female210202412
Male7378151
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CHF 1535 pMDICHF 718 pMDITotal
Hispanic or Latino154165319
Not Hispanic or Latino129113242
Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CHF 1535 pMDICHF 718 pMDITotal
American Indian or Alaska Native112
Asian369
Native Hawaiian or Other Pacific Islander112
Black or African American5949108
White216220436
More than one race213
Unknown or Not Reported123
Region of Enrollment
Region of Enrollment(Participants)CHF 1535 pMDICHF 718 pMDITotal
United States283280563
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)CHF 1535 pMDICHF 718 pMDITotal
Mean30.90 ± 6.9330.86 ± 7.2730.88 ± 7.09
Time since first asthma diagnosis
Time since first asthma diagnosis(months)CHF 1535 pMDICHF 718 pMDITotal
Mean474.6 ± 173.6468.4 ± 180.9471.5 ± 177.1

12 further baseline measures are reported on the registry.

08

Study locations

91 sites
  • Chiesi Clinical Trial Site 840858
    Mobile, Alabama 36608, United States
  • Chiesi Clinical Trial Site 840895
    Chandler, Arizona 85224, United States
  • Chiesi Clinical Trial Site 840856
    Encinitas, California 92024, United States
  • Chiesi Clinical Trial Site 840843
    Huntington Beach, California 92647, United States
  • Chiesi Clinical Trial Site 840860
    Huntington Beach, California 92647, United States
  • Chiesi Clinical Trial Site 840896
    Long Beach, California 90805, United States
  • Chiesi Clinical Trial Site 840883
    Los Angeles, California 90025, United States
  • Chiesi Clinical Trial Site 840810
    Los Angeles, California 90048, United States
  • Chiesi Clinical Trial Site 840869
    Newport Beach, California 92663, United States
  • Chiesi Clinical Trial Site 840890
    North Hollywood, California 91606, United States
  • Chiesi Clinical Trial Site 840808
    Northridge, California 91324, United States
  • Chiesi Clinical Trial Site 840879
    Pomona, California 91768, United States
  • Chiesi Clinical Trial Site 840868
    Sacramento, California 95823, United States
  • Chiesi Clinical Trial Site 840849
    San Diego, California 92120, United States
  • Chiesi Clinical Trial Site 840877
    San Diego, California 92123, United States
  • Chiesi Clinical Trial Site 840861
    San Jose, California 95117, United States
  • Chiesi Clinical Trial Site 840881
    Westminster, California 92683, United States
  • Chiesi Clinical Trial Site 840873
    Colorado Springs, Colorado 80907, United States
  • Chiesi Clinical Trial Site 840800
    Denver, Colorado 80230, United States
  • Chiesi Clinical Trial Site 840820
    Coral Gables, Florida 33134, United States
  • Chiesi Clinical Trial Site 840841
    Cutler Bay, Florida 33189, United States
  • Chiesi Clinical Trial Site 840817
    Greenacres City, Florida 33467, United States
  • Chiesi Clinical Trial Site 840822
    Hialeah, Florida 33012, United States
  • Chiesi Clinical Trial Site 840838
    Hialeah, Florida 33015, United States
  • Chiesi Clinical Trial Site 840864
    Kissimmee, Florida 34746, United States
  • Chiesi Clinical Trial Site 840814
    Miami, Florida 33125, United States
  • Chiesi Clinical Trial Site 840819
    Miami, Florida 33126, United States
  • Chiesi Clinical Trial Site 840875
    Miami, Florida 33126, United States
  • Chiesi Clinical Trial Site 840887
    Miami, Florida 33134, United States
  • Chiesi Clinical Trial Site 840821
    Miami, Florida 33136, United States
  • Chiesi Clinical Trial Site 840829
    Miami, Florida 33155, United States
  • Chiesi Clinical Trial Site 840828
    Miami, Florida 33165, United States
  • Chiesi Clinical Trial Site 840847
    Miami, Florida 33172, United States
  • Chiesi Clinical Trial Site 840818
    Miami, Florida 33174, United States
  • Chiesi Clinical Trial Site 840802
    Miami, Florida 33176, United States
  • Chiesi Clinical Trial Site 840835
    Miami, Florida 33184, United States
  • Chiesi Clinical Trial Site 840806
    Miami, Florida 33185, United States
  • Chiesi Clinical Trial Site 840855
    Miami, Florida 33186, United States
  • Chiesi Clinical Trial Site 840809
    Miami Gardens, Florida 33014, United States
  • Chiesi Clinical Trial Site 840863
    Miami Lakes, Florida 33014, United States
  • Chiesi Clinical Trial Site 840865
    Miami Lakes, Florida 33014, United States
  • Chiesi Clinical Trial Site 840831
    Miami Springs, Florida 33166, United States
  • Chiesi Clinical Trial Site 840839
    Palmetto Bay, Florida 33157, United States
  • Chiesi Clinical Trial Site 840840
    Pembroke Pines, Florida 33024, United States
  • Chiesi Clinical Trial Site 840827
    Pembroke Pines, Florida 33029, United States
  • Chiesi Clinical Trial Site 840811
    Port Saint Lucie, Florida 34952, United States
  • Chiesi Clinical Trial Site 840889
    St. Petersburg, Florida 33707, United States
  • Chiesi Clinical Trial Site 840834
    St. Petersburg, Florida 33709, United States
  • Chiesi Clinical Trial Site 840880
    St. Petersburg, Florida 33713, United States
  • Chiesi Clinical Trial Site 840807
    Tallahassee, Florida 32308, United States
  • Chiesi Clinical Trial Site 840871
    Adairsville, Georgia 30103, United States
  • Chiesi Clinical Trial Site 840824
    White Marsh, Maryland 21162, United States
  • Chiesi Clinical Trial Site 840826
    North Dartmouth, Massachusetts 02747, United States
  • Chiesi Clinical Trial Site 840859
    Columbia, Missouri 65203, United States
  • Chiesi Clinical Trial Site 840888
    Saint Charles, Missouri 63301, United States
  • Chiesi Clinical Trial Site 840846
    St Louis, Missouri 63141, United States
  • Chiesi Clinical Trial Site 840867
    Bellevue, Nebraska 68123, United States
  • Chiesi Clinical Trial Site 840897
    Henderson, Nevada 89052, United States
  • Chiesi Clinical Trial Site 840872
    North Las Vegas, Nevada 89030, United States
  • Chiesi Clinical Trial Site 840836
    Brick, New Jersey 08724, United States
  • Chiesi Clinical Trial Site 840851
    Albuquerque, New Mexico 87108, United States
  • Chiesi Clinical Trial Site 840899
    Monroe, North Carolina 28112, United States
  • Chiesi Clinical Trial Site 840852
    Raleigh, North Carolina 27607, United States
  • Chiesi Clinical Trial Site 840866
    Edmond, Oklahoma 73034, United States
  • Chiesi Clinical Trial Site 840878
    Tulsa, Oklahoma 74133, United States
  • Chiesi Clinical Trial Site 840884
    Grants Pass, Oregon 97527, United States
  • Chiesi Clinical Trial Site 840830
    Medford, Oregon 97504, United States
  • Chiesi Clinical Trial Site 840853
    Portland, Oregon 97202, United States
  • Chiesi Clinical Trial Site 840885
    Warwick, Rhode Island 02886, United States
  • Chiesi Clinical Trial Site 840892
    Anderson, South Carolina 29621, United States
  • Chiesi Clinical Trial Site 840844
    Columbia, South Carolina 29204, United States
  • Chiesi Clinical Trial Site 840850
    Greenville, South Carolina 29615, United States
  • Chiesi Clinical Trial Site 840894
    Rock Hill, South Carolina 29732, United States
  • Chiesi Clinical Trial Site 840891
    Spartanburg, South Carolina 29303, United States
  • Chiesi Clinical Trial Site 840812
    Knoxville, Tennessee 37909, United States
  • Chiesi Clinical Trial Site 840815
    Baytown, Texas 77521, United States
  • Chiesi Clinical Trial Site 840874
    Boerne, Texas 78006, United States
  • Chiesi Clinical Trial Site 840845
    Carrollton, Texas 75007, United States
  • Chiesi Clinical Trial Site 840876
    Dallas, Texas 75225, United States
  • Chiesi Clinical Trial Site 840803
    El Paso, Texas 79903, United States
  • Chiesi Clinical Trial Site 840833
    Houston, Texas 77094, United States
  • Chiesi Clinical Trial Site 840862
    McKinney, Texas 75069, United States
  • Chiesi Clinical Trial Site 840816
    McKinney, Texas 75071, United States
  • Chiesi Clinical Trial Site 840842
    San Antonio, Texas 78207, United States
  • Chiesi Clinical Trial Site 840857
    San Antonio, Texas 78215, United States
  • Chiesi Clinical Trial Site 840823
    San Antonio, Texas 78258, United States
  • Chiesi Clinical Trial Site 840801
    Sugar Land, Texas 77479, United States
  • Chiesi Clinical Trial Site 840893
    Murray, Utah 84107, United States
  • Chiesi Clinical Trial Site 840837
    Riverton, Utah 84065, United States
  • Chiesi Clinical Trial Site 840882
    Bellingham, Washington 98225, United States
  • Chiesi Clinical Trial Site 840870
    Greenfield, Wisconsin 53228, United States
09

References and documents

Publications

  • Pelaia C, Crimi C, Vatrella A, Tinello C, Terracciano R, Pelaia G. Molecular Targets for Biological Therapies of Severe Asthma. Front Immunol. 2020 Nov 30;11:603312. doi: 10.3389/fimmu.2020.603312. eCollection 2020. PubMed 33329598 ↗
  • Roger JH, Bratton DJ, Mayer B, Abellan JJ, Keene ON. Treatment policy estimands for recurrent event data using data collected after cessation of randomised treatment. Pharm Stat. 2019 Jan;18(1):85-95. doi: 10.1002/pst.1910. Epub 2018 Nov 8. PubMed 30406948 ↗
  • Kardas G, Kuna P, Panek M. Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling. Front Immunol. 2020 Jun 18;11:1134. doi: 10.3389/fimmu.2020.01134. eCollection 2020. PubMed 32625205 ↗
  • Kippelen P, Anderson SD, Hallstrand TS. Mechanisms and Biomarkers of Exercise-Induced Bronchoconstriction. Immunol Allergy Clin North Am. 2018 May;38(2):165-182. doi: 10.1016/j.iac.2018.01.008. PubMed 29631728 ↗
  • Chau-Etchepare F, Hoerger JL, Kuhn BT, Zeki AA, Haczku A, Louie S, Kenyon NJ, Davis CE, Schivo M. Viruses and non-allergen environmental triggers in asthma. J Investig Med. 2019 Oct;67(7):1029-1041. doi: 10.1136/jim-2019-001000. Epub 2019 Jul 27. PubMed 31352362 ↗
  • GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. PubMed 33069326 ↗
  • Forno E, Celedon JC. Asthma and ethnic minorities: socioeconomic status and beyond. Curr Opin Allergy Clin Immunol. 2009 Apr;9(2):154-60. doi: 10.1097/aci.0b013e3283292207. PubMed 19326508 ↗
  • Zein JG, Udeh BL, Teague WG, Koroukian SM, Schlitz NK, Bleecker ER, Busse WB, Calhoun WJ, Castro M, Comhair SA, Fitzpatrick AM, Israel E, Wenzel SE, Holguin F, Gaston BM, Erzurum SC; Severe Asthma Research Program. Impact of Age and Sex on Outcomes and Hospital Cost of Acute Asthma in the United States, 2011-2012. PLoS One. 2016 Jun 13;11(6):e0157301. doi: 10.1371/journal.pone.0157301. eCollection 2016. PubMed 27294365 ↗
  • Global Initiative for Asthma (GINA): global strategy for asthma management and prevention. 2021 update. (2021). Available from: www.ginasthma.org.
  • Davis J, Trudo F, Siddall J, Small M. Burden of asthma among patients adherent to ICS/LABA: A real-world study. J Asthma. 2019 Mar;56(3):332-340. doi: 10.1080/02770903.2018.1455858. Epub 2018 Apr 6. PubMed 29624458 ↗
  • Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE; GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44. doi: 10.1164/rccm.200401-033OC. Epub 2004 Jul 15. PubMed 15256389 ↗
  • Lee LK, Obi E, Paknis B, Kavati A, Chipps B. Asthma control and disease burden in patients with asthma and allergic comorbidities. J Asthma. 2018 Feb;55(2):208-219. doi: 10.1080/02770903.2017.1316394. Epub 2017 Jun 6. PubMed 28586296 ↗
  • Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9. PubMed 32653074 ↗
  • Sobieraj DM, Baker WL, Nguyen E, Weeda ER, Coleman CI, White CM, Lazarus SC, Blake KV, Lang JE. Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018 Apr 10;319(14):1473-1484. doi: 10.1001/jama.2018.2757. PubMed 29554174 ↗
  • Averell CM, Laliberte F, Duh MS, Wu JW, Germain G, Faison S. Characterizing Real-World Use Of Tiotropium In Asthma In The USA. J Asthma Allergy. 2019 Oct 7;12:309-321. doi: 10.2147/JAA.S216932. eCollection 2019. PubMed 31632091 ↗
  • Paggiaro P, Corradi M, Latorre M, Raptis H, Muraro A, Gessner C, Siergiejko Z, Scuri M, Petruzzelli S. High strength extrafine pMDI beclometasone/formoterol (200/6 mug) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids. BMC Pulm Med. 2016 Dec 9;16(1):180. doi: 10.1186/s12890-016-0335-9. PubMed 27938358 ↗
  • Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM; Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007 Apr;29(4):682-9. doi: 10.1183/09031936.00095906. Epub 2006 Nov 15. PubMed 17107988 ↗
  • Papi A, Paggiaro P, Nicolini G, Vignola AM, Fabbri LM; ICAT SE study group. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007 Oct;62(10):1182-8. doi: 10.1111/j.1398-9995.2007.01493.x. PubMed 17845589 ↗
  • Corradi M, Spinola M, Petruzzelli S, Kuna P. High-dose beclometasone dipropionate/formoterol fumarate in fixed-dose combination for the treatment of asthma. Ther Adv Respir Dis. 2016 Oct;10(5):492-502. doi: 10.1177/1753465816654442. Epub 2016 Jun 23. PubMed 27340255 ↗
  • Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30. PubMed 31582314 ↗
  • Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, Hanania NA, Kerstjens HAM, Kerwin E, Nathan R, Oppenheimer J, Papi A, Pascoe S, Brusselle G, Peachey G, Sule N, Tabberer M, Pavord ID. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021 Jan;9(1):69-84. doi: 10.1016/S2213-2600(20)30389-1. Epub 2020 Sep 9. PubMed 32918892 ↗
  • Fink JB, Colice GL, Hodder R. Inhaler devices for patients with COPD. COPD. 2013 Aug;10(4):523-35. doi: 10.3109/15412555.2012.761960. Epub 2013 Mar 28. PubMed 23537191 ↗
  • Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med. 2014 Jun;2(6):497-506. doi: 10.1016/S2213-2600(14)70103-1. PubMed 24899370 ↗
  • Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med. 2006 Apr;100(4):616-21. doi: 10.1016/j.rmed.2005.08.012. Epub 2005 Oct 13. PubMed 16226443 ↗
  • Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999 Oct;14(4):902-7. doi: 10.1034/j.1399-3003.1999.14d29.x. PubMed 10573240 ↗
  • Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004 Jul;126(1):213-9. doi: 10.1378/chest.126.1.213. PubMed 15249465 ↗
  • Ellepola AN, Samaranayake LP. Inhalational and topical steroids, and oral candidosis: a mini review. Oral Dis. 2001 Jul;7(4):211-6. PubMed 11575870 ↗
  • Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009 Jul 1;180(1):59-99. doi: 10.1164/rccm.200801-060ST. PubMed 19535666 ↗
  • Virchow JC, Backer V, de Blay F, Kuna P, Ljorring C, Prieto JL, Villesen HH. Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement. Respir Med. 2015 May;109(5):547-56. doi: 10.1016/j.rmed.2015.01.012. Epub 2015 Feb 3. PubMed 25676887 ↗
  • Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST. PubMed 31613151 ↗
  • Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312. Epub 2012 Jun 27. PubMed 22743675 ↗
  • Fagerland MW, Lydersen S, Laake P. Recommended confidence intervals for two independent binomial proportions. Stat Methods Med Res. 2015 Apr;24(2):224-54. doi: 10.1177/0962280211415469. Epub 2011 Oct 13. PubMed 21996567 ↗
  • Weinstein S, Legramandi L, Mathews KS, Passineau H, Seregni L, Gandini G, Cretarola L, Foti M, Skloot G, Hernandez G. Improved lung function with beclomethasone/formoterol versus beclomethasone alone in asthma: the FORCE2 study. J Asthma. 2026 Mar;63(3):305-311. doi: 10.1080/02770903.2025.2589794. Epub 2025 Nov 22. PubMed 41231513 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jun 2024, 21 months.

Results were first posted in Sep 2025, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 21 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2022
First posted
Mar 23, 2022
StartActual
Aug 31, 2022
Primary completionActual
Jun 24, 2024
CompletionActual
Jun 24, 2024
Results first posted
Sep 4, 2025
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05292586
Responsible party
Sponsor
First posted
Mar 23, 2022
Start date
Aug 31, 2022
Primary completion
Jun 24, 2024
Completion
Jun 24, 2024
Results posted
Sep 4, 2025
Last update
Jul 20, 2026

Study contacts

Steven F. Weinstein, M.D.
principal investigator · Allergy and Asthma Specialists Medical Group and Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Formoterol

Start the discussion